[Study on relationship of biodegradable properties of PGLA film in vivo and in vitro].

Sheng Wu Yi Xue Gong Cheng Xue Za Zhi

No. 9 People's Hospital, Shanghai Second Medical University, Shanghai Biomaterial Research and Test Center, Shanghai 200023, China.

Published: October 2004

This experimental study on the biodegradable properties of poly(glycolide-co-lactide)[PGLA] film in vivo and in vitro was aimed to investigate the relationship between in vivo degradation process and in vitro degradation process. First, PGLA film was cut to 1 cm x 1 cm in size. It was put into artificial saliva and PBS solution respectively in vitro, and was implanted into subcutaneous tissue in Wistar rat in vivo. Then the mass loss rate was calculated every week not only for sample in vitro but also in vivo. The molecular weight was measured every two weeks. The results showed that the degradable speed of PGLA was faster in artificial saliva than in PBS solution. The change of molecular weight was earlier than that of mass loss rate. The degradable period in vitro was about 9-10 weeks. The degradable period in vivo was about 8 weeks. The rate of in vivo degradation was 1.33 times faster than that of in vitro. In conclusion, the degradation of PGLA in vitro was mainly a chemical degradation process achieved by hydrolysis of ester bond. The degradation of PGLA in vivo would be affected by stress and by biological factors, thus the degradation process was apparently faster in vivo, but both accorded with the degradation kinetics model of aliphatic polyester. There was some relationship of biodegradation between in vitro and in vivo.

Download full-text PDF

Source

Publication Analysis

Top Keywords

degradation process
16
vivo
10
biodegradable properties
8
pgla film
8
film vivo
8
vitro
8
degradation
8
vivo degradation
8
artificial saliva
8
saliva pbs
8

Similar Publications

Background: The TREAT-AD centers aim to improve Alzheimer's Disease (AD) research by offering free, high-quality tools and technologies. Lyn is a tyrosine kinase that belongs to the Src family kinases. The expression of Lyn and its activity have been implicated in AD.

View Article and Find Full Text PDF

Drug Development.

Alzheimers Dement

December 2024

Athira Pharma, Inc., Bothell, WA, USA.

Background: Accumulating evidence highlights impairment of autophagy as a key pathological feature of neurodegenerative diseases including Alzheimer's disease (AD). Autophagy is a highly dynamic, lysosome-based degradation process that promotes the clearance of degenerative factors to maintain cellular functions, preserve metabolic integrity, and ensure survival. Impaired autophagic function leads to the abnormal accumulation of autophagic vesicles (i.

View Article and Find Full Text PDF

Background: TAR-DNA-binding protein 43 (TDP43), is a pathologic marker in neurodegenerative diseases including frontotemporal lobar degeneration and amyotrophic lateral sclerosis. The aggregation of TDP-43, a crucial RNA-binding protein, is a consequence of post-translational modifications (PTMs) that disrupt its normal function. PTMs such as phosphorylation and ubiquitination contribute to the aberrant accumulation of TDP-43 aggregates, leading to neurodegenerative disorders like amyotrophic lateral sclerosis (ALS) and frontotemporal lobar degeneration (FTLD).

View Article and Find Full Text PDF

Drug Development.

Alzheimers Dement

December 2024

Division of Neurodegenerative Disorders, St. Boniface Hospital Albrechtsen Research Centre, Winnipeg, MB, Canada.

Background: Alzheimer's disease (AD) is a neurodegenerative disorder primarily associated with aging, but manifests as a complex interplay of multiple factors. Decline in sex-hormones, particularly 17-beta estradiol, is linked to the aging process. The risk for onset of AD significantly increases with aging and loss of estradiol.

View Article and Find Full Text PDF

Drug Development.

Alzheimers Dement

December 2024

Department of Neurosciences, University of California, San Diego, La Jolla, CA, USA.

Background: Increased APP gene dosage is both necessary and sufficient to result in Down Syndrome Alzheimer's Disease (DSAD) in humans and AD-related degenerative changes in mouse models of DS.

Method: We tested antisense oligonucleotides (ASOs) designed to suppress APP expression via RNAseH1-mediated degradation in the Dp(16)1Yey or Dp(16) model of Down Syndrome. Dp(16) is trisomic for human chromosome 21 syntenic regions on murine chromosome 16, containing 115 genes including APP.

View Article and Find Full Text PDF

Want AI Summaries of new PubMed Abstracts delivered to your In-box?

Enter search terms and have AI summaries delivered each week - change queries or unsubscribe any time!